Trial Profile
A Phase Ib/II, Open-label, Multicenter Study of Oral HDM201 in Combination With Oral LEE011 in Adult Patients With Liposarcoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Ribociclib (Primary) ; Siremadlin (Primary)
- Indications Liposarcoma
- Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 17 Dec 2021 Results published in the Clinical Cancer Research
- 17 Jan 2020 Status changed from active, no longer recruiting to completed.
- 13 Jun 2019 Planned End Date changed from 28 Jun 2019 to 6 Sep 2019.